Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
MGNX's Cash-to-Debt is ranked higher than
73% of the 864 Companies
in the Global Biotechnology industry.

( Industry Median: 53.59 vs. MGNX: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
MGNX' s Cash-to-Debt Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.86
MGNX's Equity-to-Asset is ranked higher than
77% of the 635 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. MGNX: 0.86 )
Ranked among companies with meaningful Equity-to-Asset only.
MGNX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.28  Med: 0.66 Max: 0.87
Current: 0.86
-0.28
0.87
Interest Coverage No Debt
MGNX's Interest Coverage is ranked higher than
68% of the 490 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. MGNX: No Debt )
Ranked among companies with meaningful Interest Coverage only.
MGNX' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: 8.84
Beneish M-Score: 0.06
WACC vs ROIC
29.98%
-25419.98%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating Margin % -65.35
MGNX's Operating Margin % is ranked higher than
54% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -97.80 vs. MGNX: -65.35 )
Ranked among companies with meaningful Operating Margin % only.
MGNX' s Operating Margin % Range Over the Past 10 Years
Min: -80.16  Med: -9.69 Max: 12.86
Current: -65.35
-80.16
12.86
Net Margin % -63.70
MGNX's Net Margin % is ranked higher than
53% of the 661 Companies
in the Global Biotechnology industry.

( Industry Median: -83.37 vs. MGNX: -63.70 )
Ranked among companies with meaningful Net Margin % only.
MGNX' s Net Margin % Range Over the Past 10 Years
Min: -80.16  Med: -10.21 Max: 13.1
Current: -63.7
-80.16
13.1
ROE % -19.53
MGNX's ROE % is ranked higher than
64% of the 773 Companies
in the Global Biotechnology industry.

( Industry Median: -39.29 vs. MGNX: -19.53 )
Ranked among companies with meaningful ROE % only.
MGNX' s ROE % Range Over the Past 10 Years
Min: -38.27  Med: -14.69 Max: -0.74
Current: -19.53
-38.27
-0.74
ROA % -17.16
MGNX's ROA % is ranked higher than
63% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: -33.51 vs. MGNX: -17.16 )
Ranked among companies with meaningful ROA % only.
MGNX' s ROA % Range Over the Past 10 Years
Min: -25.57  Med: -3.93 Max: 14.36
Current: -17.16
-25.57
14.36
ROC (Joel Greenblatt) % -203.94
MGNX's ROC (Joel Greenblatt) % is ranked higher than
59% of the 827 Companies
in the Global Biotechnology industry.

( Industry Median: -476.30 vs. MGNX: -203.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MGNX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -648.31  Med: -88.92 Max: 250.31
Current: -203.94
-648.31
250.31
3-Year Revenue Growth Rate -32.10
MGNX's 3-Year Revenue Growth Rate is ranked lower than
78% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 4.80 vs. MGNX: -32.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MGNX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -68.5  Med: -62.2 Max: -32.1
Current: -32.1
-68.5
-32.1
3-Year EPS without NRI Growth Rate 248.30
MGNX's 3-Year EPS without NRI Growth Rate is ranked higher than
100% of the 501 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. MGNX: 248.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MGNX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: 248.3
Current: 248.3
0
248.3
» MGNX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-28 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

MGNX Guru Trades in Q1 2016

Steven Cohen 2,330,200 sh (+10.34%)
Ronald Muhlenkamp 67,245 sh (+1.26%)
John Griffin 1,360,000 sh (+0.74%)
George Soros 19,488 sh (unchged)
Julian Robertson 575,129 sh (unchged)
First Eagle Investment 285,800 sh (-1.45%)
Jim Simons 20,723 sh (-77.64%)
» More
Q2 2016

MGNX Guru Trades in Q2 2016

Paul Tudor Jones 12,858 sh (New)
Steven Cohen 2,554,900 sh (+9.64%)
John Griffin 1,360,000 sh (unchged)
Jim Simons Sold Out
George Soros Sold Out
First Eagle Investment 221,800 sh (-22.39%)
Julian Robertson 313,140 sh (-45.55%)
Ronald Muhlenkamp 15,835 sh (-76.45%)
» More
Q3 2016

MGNX Guru Trades in Q3 2016

Paul Tudor Jones 15,542 sh (+20.87%)
First Eagle Investment 221,800 sh (unchged)
John Griffin 1,360,000 sh (unchged)
Julian Robertson 266,067 sh (-15.03%)
Ronald Muhlenkamp 12,162 sh (-23.20%)
Steven Cohen 1,813,300 sh (-29.03%)
» More
Q4 2016

MGNX Guru Trades in Q4 2016

Ronald Muhlenkamp 12,803 sh (+5.27%)
John Griffin 1,360,000 sh (unchged)
Paul Tudor Jones 14,959 sh (-3.75%)
Julian Robertson 239,667 sh (-9.92%)
First Eagle Investment 175,000 sh (-21.10%)
Steven Cohen 1,213,117 sh (-33.10%)
» More
» Details

Insider Trades

Latest Guru Trades with MGNX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BCRX, NAS:ANIP, NAS:BSTC, AMEX:BTX, NAS:CASC, NAS:BDSI, NAS:BMRN » details
Traded in other countries:M55.Germany,
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

Ratios

vs
industry
vs
history
PB Ratio 2.48
MGNX's PB Ratio is ranked higher than
67% of the 1091 Companies
in the Global Biotechnology industry.

( Industry Median: 3.76 vs. MGNX: 2.48 )
Ranked among companies with meaningful PB Ratio only.
MGNX' s PB Ratio Range Over the Past 10 Years
Min: 1.73  Med: 3.63 Max: 12.83
Current: 2.48
1.73
12.83
PS Ratio 7.29
MGNX's PS Ratio is ranked higher than
66% of the 854 Companies
in the Global Biotechnology industry.

( Industry Median: 12.99 vs. MGNX: 7.29 )
Ranked among companies with meaningful PS Ratio only.
MGNX' s PS Ratio Range Over the Past 10 Years
Min: 1.12  Med: 8.6 Max: 24.45
Current: 7.29
1.12
24.45
Current Ratio 10.40
MGNX's Current Ratio is ranked higher than
81% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. MGNX: 10.40 )
Ranked among companies with meaningful Current Ratio only.
MGNX' s Current Ratio Range Over the Past 10 Years
Min: 1.32  Med: 5.11 Max: 14.15
Current: 10.4
1.32
14.15
Quick Ratio 10.40
MGNX's Quick Ratio is ranked higher than
81% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. MGNX: 10.40 )
Ranked among companies with meaningful Quick Ratio only.
MGNX' s Quick Ratio Range Over the Past 10 Years
Min: 1.32  Med: 5.11 Max: 14.15
Current: 10.4
1.32
14.15
Days Sales Outstanding 10.98
MGNX's Days Sales Outstanding is ranked higher than
87% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 59.11 vs. MGNX: 10.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
MGNX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.43  Med: 12.15 Max: 22.41
Current: 10.98
4.43
22.41

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -11.50
MGNX's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 563 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. MGNX: -11.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MGNX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -216.5  Med: -201.1 Max: -11.5
Current: -11.5
-216.5
-11.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 2.80
MGNX's Price-to-Net-Cash is ranked higher than
78% of the 739 Companies
in the Global Biotechnology industry.

( Industry Median: 6.36 vs. MGNX: 2.80 )
Ranked among companies with meaningful Price-to-Net-Cash only.
MGNX' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.6  Med: 6.49 Max: 9.94
Current: 2.8
2.6
9.94
Price-to-Net-Current-Asset-Value 2.72
MGNX's Price-to-Net-Current-Asset-Value is ranked higher than
77% of the 870 Companies
in the Global Biotechnology industry.

( Industry Median: 5.79 vs. MGNX: 2.72 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MGNX' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.53  Med: 6.18 Max: 9.52
Current: 2.72
2.53
9.52
Price-to-Tangible-Book 2.44
MGNX's Price-to-Tangible-Book is ranked higher than
74% of the 1017 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. MGNX: 2.44 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MGNX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.27  Med: 5.75 Max: 8.75
Current: 2.44
2.27
8.75
Price-to-Median-PS-Value 0.85
MGNX's Price-to-Median-PS-Value is ranked higher than
65% of the 750 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. MGNX: 0.85 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MGNX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1.03 Max: 2.31
Current: 0.85
0.14
2.31
Earnings Yield (Greenblatt) % -15.91
MGNX's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 1273 Companies
in the Global Biotechnology industry.

( Industry Median: -8.24 vs. MGNX: -15.91 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MGNX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -18.16  Med: 0.2 Max: 1.5
Current: -15.91
-18.16
1.5

More Statistics

Revenue (TTM) (Mil) $91.88
EPS (TTM) $ -1.73
Beta3.65
Short Percentage of Float10.09%
52-Week Range $15.53 - 33.30
Shares Outstanding (Mil)34.97

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 38 44 15
EPS ($) -3.70 -3.83 -4.69
EPS without NRI ($) -3.70 -3.83 -4.69
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MGNX

Headlines

Articles On GuruFocus.com
Julian Robertson Sells Delta Air Lines, Alphabet Dec 07 2016 
Ronald Muhlenkamp Sells Allegiant, Microsoft, Apple Aug 15 2016 
Weekly 3-Year Low Highlights: KN, MGNX, MIXT, EDMC May 27 2014 

More From Other Websites
MacroGenics to Present at the Needham Healthcare Conference Mar 29 2017
MacroGenics, Inc. breached its 50 day moving average in a Bearish Manner : MGNX-US : March 14, 2017 Mar 14 2017
MACROGENICS INC Financials Mar 07 2017
MacroGenics, Inc. :MGNX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
Wedbush Has 3 Biotech Stocks to Buy With Massive Upside Potential Mar 03 2017
Coverage initiated on MacroGenics by Instinet Mar 02 2017
Edited Transcript of MGNX earnings conference call or presentation 28-Feb-17 9:30pm GMT Mar 01 2017
MACROGENICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 28 2017
MACROGENICS INC Files SEC form 10-K, Annual Report Feb 28 2017
MacroGenics Provides Update on Corporate Progress and 2016 Financial Results Feb 28 2017
Q4 2016 MacroGenics Inc Earnings Release - After Market Close Feb 28 2017
MacroGenics to Participate in Two Upcoming Investor Conferences Feb 27 2017
MacroGenics Announces Date of Fourth Quarter and Full Year 2016 Financial Results Conference Call Feb 16 2017
MacroGenics to Present at the Leerink Partners 6th Annual Global Healthcare Conference Feb 09 2017
3 Greater Washington biotech execs sign industry letter opposing the Trump travel ban Feb 08 2017
MACROGENICS INC Files SEC form 8-K, Financial Statements and Exhibits Jan 26 2017
MacroGenics Announces Appointments to Board of Directors Jan 25 2017
D.C.-area biotech stocks fall on Trump's tough talk on industry Jan 11 2017
5 Stocks Setting Up for Big Breakouts Jan 06 2017
MacroGenics' MGD006 Granted Orphan Drug Status for AML by FDA Jan 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)